NuCana (NCNA) Retained Earnings (2015 - 2025)
NuCana (NCNA) reported Retained Earnings of $115.8 million for Q4 2025, up 15.07% on a YoY basis from $100.7 million in Q4 2024, and down 0.88% sequentially from $116.9 million in Q3 2025.
NuCana (NCNA) Retained Earnings (2015 - 2025) Analysis & Trends
NuCana (NCNA) has 11 years of Retained Earnings data on file, last reported at $115.8 million in Q4 2025.
- For the quarter ending Q4 2025, Retained Earnings rose 15.07% year-over-year to $115.8 million; the trailing twelve-month figure through Dec 2025 stood at $115.8 million (up 15.07% YoY), and the FY2025 full-year result was $114.8 million, up 14.53% from the prior year.
- Retained Earnings fell to $115.8 million in Q4 2025, from $116.9 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $116.9 million in Q3 2025 to a low of $88.5 million in Q3 2022.
- A 5-year average of $99.6 million and a median of $98.4 million in 2022 frame the typical range for Retained Earnings.
- Across the five-year window, Retained Earnings advanced 21.06% in 2021 and retreated 8.84% in 2022, its largest moves.
- Tracing NCNA's Retained Earnings over 5 years: stood at $97.2 million in 2021, then declined by 8.48% to $89.0 million in 2022, then advanced by 10.42% to $98.3 million in 2023, then grew by 2.43% to $100.7 million in 2024, then advanced by 15.07% to $115.8 million in 2025.
- Business Quant data shows NCNA's Retained Earnings at $115.8 million in Q4 2025, $116.9 million in Q3 2025, and $115.3 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | -24.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 115.82 Mn |
| Sep 30, 2025 | 116.85 Mn |
| Jun 30, 2025 | 115.27 Mn |
| Mar 31, 2025 | 99.01 Mn |
| Dec 31, 2024 | 100.65 Mn |
| Sep 30, 2024 | 101.87 Mn |
| Jun 30, 2024 | 98.92 Mn |
| Mar 31, 2024 | 101.02 Mn |
| Dec 31, 2023 | 98.27 Mn |
| Sep 30, 2023 | 99.35 Mn |
| Jun 30, 2023 | 97.24 Mn |
| Mar 31, 2023 | 93.48 Mn |
| Dec 31, 2022 | 88.99 Mn |
| Sep 30, 2022 | 88.47 Mn |
| Jun 30, 2022 | 94.00 Mn |
| Mar 31, 2022 | 98.60 Mn |
| Dec 31, 2021 | 97.24 Mn |
| Sep 30, 2021 | 97.05 Mn |
| Jun 30, 2021 | 96.74 Mn |
| Mar 31, 2021 | 93.04 Mn |